These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

842 related articles for article (PubMed ID: 17335684)

  • 1. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and the current trends in multiple myeloma therapy.
    Dmoszyńska A
    Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical update: novel targets in multiple myeloma.
    Anderson KC
    Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma: novel approaches for relapsed disease.
    Lonial S
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S18-23. PubMed ID: 18282362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
    Barlogie B
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapies in multiple myeloma.
    Merchionne F; Perosa F; Dammacco F
    Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed and refractory myeloma.
    Kaufman J; Gleason C; Lonial S
    Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving role of novel agents for maintenance therapy in myeloma.
    Magarotto V; Palumbo A
    Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
    Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL
    Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New treatment of multiple myeloma].
    Hulin C
    Rev Med Interne; 2007 Oct; 28(10):682-8. PubMed ID: 17559982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of double-refractory multiple myeloma.
    Meadows JP; Mark TM
    Curr Hematol Malig Rep; 2013 Dec; 8(4):253-60. PubMed ID: 23975677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma: improved outcomes with new therapeutic approaches.
    Eshaghian S; Berenson JR
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):330-6. PubMed ID: 22871979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
    Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
    Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
    Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG
    Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.